Athersys (ATHX) Trading Up 7.2%
Athersys, Inc. (NASDAQ:ATHX) shares traded up 7.2% during trading on Monday . The stock traded as high as $1.84 and last traded at $1.79. 1,534,248 shares traded hands during trading, an increase of 51% from the average session volume of 1,017,098 shares. The stock had previously closed at $1.67.
Several research analysts recently commented on the stock. ValuEngine cut shares of Athersys from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Zacks Investment Research cut shares of Athersys from a “buy” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, Maxim Group restated a “buy” rating and set a $12.00 target price on shares of Athersys in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.17.
In other Athersys news, COO William Lehmann, Jr. sold 14,000 shares of the stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $1.80, for a total value of $25,200.00. Following the completion of the sale, the chief operating officer now owns 503,712 shares in the company, valued at $906,681.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 29,000 shares of company stock valued at $51,075. Corporate insiders own 9.40% of the company’s stock.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.